Still, when considering KRAS, the overwhelming majority of substitutions occur on residues 12, 13, and 61 for both colorectal and lung cancer, implying that while the mutational landscape may vary, it does not have a significant effect on mutation location and thus would not violate the uniformity assumption. Here, KRAS is linked to lung carcinoma.